Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2807/1560-7917.ES.2021.26.28.2100634 http://scihub22266oqcxt.onion/10.2807/1560-7917.ES.2021.26.28.2100634 34269172!8284043!34269172     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34269172&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Euro+Surveill 2021 ; 26 (28): ? Nephropedia Template TP {{tp|p=34269172|t=2021. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England |pdf=|usr=}}{{34269172}} gab.com Text Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England JO: Euro Surveill http://www.kidney.de/pget.php?&tw=1&pmid=34269172 #FOAvip Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among </= 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57.8-87.9). Twit Text FOAVip Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England ????Euro Surveill http://www.kidney.de/pget.php?&tw=1&pmid=34269172 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34269172 #FOAvip English Wikipedia <ref>{{Cite pmid|34269172}}</ref> Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England #MMPMID34269172 Powell AA; Power L; Westrop S; McOwat K; Campbell H; Simmons R; Ramsay ME; Brown K; Ladhani SN; Amirthalingam G Euro Surveill 2021[Jul]; 26 (28): ? PMID34269172show ga Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57.8-87.9). |*COVID-19[MESH] |*COVID-19 Vaccines[MESH] |Adult[MESH] |England/epidemiology[MESH] |Female[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Real-world data shows increased reactogenicity in adults after heterol(epmc).pdf DeepDyve Pubget Overpricing